ArticleBiomedical reports2025
Analysis of conditioning with dexmedetomidine under endothelial dysfunction in isolated perfused hearts.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardioprotective strategies such as pharmacological conditioning have not yet successfully undergone bench-to-bedside transfer, which is probably due to inhibition of cardioprotection by comorbidities or associated pathological changes. Endothelial dysfunction (ED) is closely associated with most cardiovascular diseases and their typical comorbidities. Therefore, cardioprotective strategies should be examined under ED. It was previously demonstrated that dexmedetomidine (DEX) maintains its cardioprotective properties against ischemia/reperfusion (I/R) injury under hyperglycaemia in the setting of pre-but not postconditioning, using a constant pressure Langendorff system. Under ED, cardioprotection by DEX preconditioning is also maintained using a constant flow mode, whereas this has not yet been investigated for postconditioning. Because DEX has vasoconstrictive properties, different haemodynamic conditions might influence the cardioprotective potential of DEX. Therefore, it was investigated whether pre- and postconditioning protocols with DEX used in constant pressure mode are transferable to constant flow mode and whether the cardioprotective effect of DEX is maintained under ED. The cardioprotective effect against I/R injury of pre- and post-treatment with 3 nM DEX on isolated-perfused hearts of male Wistar rats was analysed in constant flow mode. ED was induced by perfusion with Krebs-Henseleit buffer containing 60 mM KCl. Heart function was assessed via pressure measurements in the left ventricle (LV) and infarct size (IS) via triphenyltetrazolium-chloride staining. In constant flow mode, pre- and post-treatment with DEX has no effect on IS and heart function compared with hearts treated with vehicle both under ED and under physiological conditions. In DEX pre-treated hearts under ED, LV developed pressure is increased and contractility is improved after 60 min of reperfusion. Pre- and post-treatment with DEX is not cardioprotective with the protocol used, while DEX pre-treatment under ED has improving effects on heart function. Different hemodynamic conditions may modulate the cardioprotective properties of DEX, possibly due to its vasoconstrictive properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.